S5 Full cost-effectiveness results for overall and subgroup populations under the PAS price Mean Mean ICER Population Intervention QALYs (£/QALY) (£) Adults and adolescents (≥ 12 years of age) age at model entry: 43 years – Standard 33,153 13.66 care Overall Omalizumab 60,406 14.14 57,557 patient Children (6-11 of age) age at – population model entry: 9 years Standard care 40,575 16.72 Omalizumab 76,386 17.39 53,348 Adults and adolescents (≥ 12 years of age) age at model entry: 43 years – Standard care 36,531 11.83 Omalizumab 31,782 Hospitalisation 63,410 12.68 Children (6-11 years of age) age at – model entry: 9 years Standard care 44,871 14.45 Omalizumab 70,967 15.32 30,109
S5 Full cost-effectiveness results for overall and subgroup populations under the PAS price Population Intervention Mean (£) Mean QALYs ICER (£/QALY) Overall patient population Adults and adolescents (≥ 12 years of age) – age at model entry: 43 years Standard care 33,153 13.66 Omalizumab 60,406 14.14 57,557 Children (6-11 of age) – age at model entry: 9 years Standard care 40,575 16.72 Omalizumab 76,386 17.39 53,348 Hospitalisation Adults and adolescents (≥ 12 years of age) – age at model entry: 43 years Standard care 36,531 11.83 Omalizumab 63,410 12.68 31,782 Children (6-11 years of age) – age at model entry: 9 years Standard care 44,871 14.45 Omalizumab 70,967 15.32 30,109
1-s2.0-S1098301514019330-mmc1.docx